Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$20.51 USD
-1.09 (-5.05%)
Updated Apr 18, 2024 03:59 PM ET
After-Market: $20.54 +0.03 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Akero Therapeutics, Inc. (AKRO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$49.13 | $60.00 | $36.00 | 127.45% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Akero Therapeutics, Inc. comes to $49.13. The forecasts range from a low of $36.00 to a high of $60.00. The average price target represents an increase of 127.45% from the last closing price of $21.60.
Analyst Price Targets (8 )
Broker Rating
Akero Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
2/1/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
12/26/2023 | LifeSci Capital | Rami Katkhuda | Not Available | Strong Buy |
10/4/2023 | Cantor Fitzgerald & Co | Prakhar Agrawal | Strong Buy | Strong Buy |
9/13/2023 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $49.13 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 252 |
Current Quarter EPS Est: | -0.99 |